Recruiting Clinical Trials

Autologous Dendritic Cell Vaccination in Mesothelioma

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 20

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: CCRG13-002

Study First Received: December 7, 2015

Last Updated: January 24, 2017

Estimated Primary Completion Date: October 2020


Primary Outcome Measures:

Number of MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicity

Sponsors and Collaborators:

University Hospital, Antwerp

Website Link:

Leave a Reply

Call Now ButtonCall Now